HC Wainwright Forecasts Strong Price Appreciation for Actuate Therapeutics (NASDAQ:ACTU) Stock
Actuate Therapeutics (NASDAQ:ACTU – Get Free Report) had its target price boosted by stock analysts at HC Wainwright to $20.00 in a research note issued on Tuesday, Stock Target Advisor reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 119.54% from the stock’s […]
Actuate Therapeutics (NASDAQ:ACTU – Get Free Report) had its target price boosted by stock analysts at HC Wainwright to $20.00 in a research note issued on Tuesday, Stock Target Advisor reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 119.54% from the stock’s […]
